Placeholder Photo

Jeb Ledell, BS

Boston, Massachusetts, United States
Mr. Ledell serves as Chief Operating Officer of AVEO. He joined AVEO from Enzyvant Therapeutics, a biotechnology company dedicated to developing novel, transformative regenerative therapies for people with devastating rare diseases, where he served as Chief Operating Officer and led key business operations during the recent U.S. Food and Drug Administration approval of RETHYMIC®. Prior to Enzyvant, Mr. Ledell served as the Chief Operating Officer at Compass Therapeutics and Horizon Discovery Group. He was responsible for leading operations at both organizations through several changes in scale. Prior to Horizon, he held multiple technology, operations and development roles at Zalicus Inc. Mr. Ledell holds a BS degree in Chemical Engineering from Worcester Polytechnic Institute.
Speaking In
1:45 PM - 2:00 PM
Monday, June 5
AVEO Oncology, an LG Chem Company, is a commercial stage, oncology-focused biopharmaceutical…
Session Room 103